跳至主要内容
临床试验/NCT04046952
NCT04046952终止不适用

Radial Hemostasis is Facilitated With a Potassium Ferrate Hemostatic Patch (Statseal): the Randomized Controlled Statseal With TR Band Assessment Trial (STAT) II

VA Long Beach Healthcare System2 个研究点 分布在 1 个国家目标入组 443 人开始时间: 2019年10月10日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
443
试验地点
2
主要终点
Time to Hemostasis Using the Hemostasis Management System (HMS)

研究概览

简要总结

The purpose of this clinical study is to compare how well two different devices for achieving hemostasis perform in patients undergoing transradial procedures. Both devices are approved by the FDA for this use, and have already been used by clinicians on patients undergoing transradial procedures. It is believed that the use of both devices in combination compared to the hemostasis band (TR band) alone will shorten the time that it takes to 'seal' the artery, resulting in a shorter period of time that you would need to wear the hemostasis band.

详细描述

This study is a physician initiated, prospective, observational, two arm, randomized study to be performed at experienced 'Radial First' centers. Patients having undergone successful radial catheterization will be enrolled in the study. Enrollment with continue at each site with an initial goal of 800 patients enrolled, with each center contributing a minimum of 50 patients. Study will be have a single interim analysis after 400 patients are enrolled for efficacy and safety and continuation of the study. Clinicians will perform the catheterization in accordance with local standard practice, with no minimum amount of anticoagulation required.

Unlike the pilot trial of this device, the present study will have an identical time to first deflation of 60 minutes between the two groups, and have a larger sample size to detect any excess risk of hematoma or radial artery occlusion. The study may also help demonstrate a relatively low rate of radial artery occlusion with a rapid deflation protocol, even at lower doses of unfractionated heparin than currently recommended.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient undergoing diagnostic angiography or PCI via the radial artery
  • Patients with a Barbeau test prior to the procedure showing pattern A,B,or C.

排除标准

  • any one of the following...
  • Use of a radial sheath larger than 6 Fr (a 7Fr-in-6 Glidesheath Slender ® is allowed).
  • Use of a hemostasis method or device besides the TR Band.
  • Patients undergoing catheterization from the femoral, brachial, ulnar, or distal radial (snuffbox) artery approach.
  • Use of an anticoagulant other than unfractionated heparin or bivalirudin.
  • Any use of glycoprotein inhibitors or cangrelor.
  • Use of sheathless guides.
  • Any anticipated need for continued anticoagulation post-catheterization, including extended bivalirudin infusion.
  • Any active treatment with oral anticoagulants continued during course of procedure.
  • Presence of arteriovenous dialysis fistula in the ipsilateral arm.
  • Any physical deformity or trauma / injury of either wrist that would prevent proper placement or function of the hemostasis band.
  • Raynaud's syndrome or known peripheral vascular disease of the forearm.
  • Inability of the patient to personally consent for the study. (no surrogate consent)
  • History or presence of Radial Artery Occlusion.
  • Barbeau test showing Pattern D.
  • Cardiogenic shock or any clinical instability as assessed by the physician performing the procedure.

结局指标

主要结局

Time to Hemostasis Using the Hemostasis Management System (HMS)

时间窗: Within 30 minutes of discharge or 24 hours post procedure (± 1 hour), whichever occurs first.

Time to deflation for removal of the TR Band (or TR Band and Statseal) for each group was measured in minutes.

次要结局

  • Percent of Patients With Radial Artery Occlusion (RAO)(Within 30 minutes of discharge or 24 hours post procedure (± 1 hour), whichever occurs first.)

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Arnold Seto

VA Long Beach Chief of Cardiology, Director of Interventional Cardiology Research

VA Long Beach Healthcare System

研究点 (2)

Loading locations...

相似试验